Clinical trials: Peripheral Vascular Diseases
Peripheral Arterial Disease
ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study
The objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the StellarexTM 0.014" OTW Drug-coated Angioplasty Balloon in the treatment of lesions in "below the…
- Trial name
- BTK PMS (NCT03395236)
- Testing
- StellarexTM 0.014" Over-The-Wire Drug-coated Angioplasty Balloon
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 49 people
- Sponsor
- Spectranetics Corporation
Peripheral Artery Disease, Critical Limb Ischemia
Complete Lesion Assessment With ffR and IVUS TechnologY
CLARITY I is a pilot study to identify the clinically appropriate endpoint(s) of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia (CLI).
- Trial name
- CLARITY I (NCT01941030)
- Testing
- Orbital Atherectomy System, Balloon Angioplasty
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Abbott Medical Devices
Carotid Atherosclerosis, Peripheral Arterial Disease
Non-invasive Computer-Aided Phenotyping of Vasculopathy
The investigators use MRI and/or CT to evaluate the extent, as well as, the structure, composition, and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in patients scheduled to undergo an…
- Trial name
- Q-CAMP (NCT02143102)
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Elucid Bioimaging Inc.
Intermittent Claudication
Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 50 mg, to PLETAL® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00602407
- Testing
- Cilostazol
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Peripheral Arterial Disease
A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions
To evaluate the bioequivalence and safety of AJU-B718 and B718R in Healthy Adults.
- Trial name
- NCT07901088
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Peripheral Artery Disease, Vascular Disease
Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with…
- Conditions
- Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease, Intermittent Claudication
- Trial name
- PAD (NCT02121288)
- Testing
- Ticagrelor, clopidogrel
- Sponsor
- AstraZeneca
Peripheral Vascular Disease, Intermittent Claudication
Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication
The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market.
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Walking, Difficulty, Critical Limb Ischemia
- Trial name
- FlowOx (NCT04100681)
- Testing
- Active FlowOx™
- Where
- 5 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Otivio AS
Intermittent Claudication
Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication
The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.
- Trial name
- NCT00783081
- Testing
- K-134, Cilostazol 100 mg BID
- Where
- 42 sites in United States, Russia
- Volunteers
- 387 people
- Sponsor
- Kowa Research Institute, Inc.
Peripheral Arterial Disease
Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
The PID-PAB study aims to test the efficacy of the European Guidelines on Cardiovascular Disease Prevention in patients with peripheral arterial disease.
- Trial name
- PID-PAB (NCT00761969)
- Testing
- Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice
- Where
- Slovenia
- Volunteers
- 1,455 people, healthy volunteers welcome
- Sponsor
- KRKA
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL)
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies.
- Conditions
- Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04072458
- Testing
- L-Bcl-2 antisense oligonucleotide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bio-Path Holdings, Inc.
Vascular Disease, Peripheral
3 Month PHI PAD PoM Study
This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g.
- Trial name
- NCT02135848
- Testing
- GSK1278863
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- GlaxoSmithKline
Arterial Occlusive Diseases
A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion
The purpose of this study is to evaluate the safety of increasing doses of intra-thrombus Plasmin (Human) in acute peripheral arterial occlusion (aPAO).
- Trial name
- PRIORITY (NCT00418483)
- Testing
- Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Grifols Therapeutics LLC
Peripheral Arterial Disease
Rapamycin Coated Balloon Dilation Catheter for Arteriovenous Fistula
Verify the effectiveness and safety of rapamycin coated balloon dilation catheter for the treatment of dialysis pathway stenosis or blockage lesions.
- Trial name
- NCT06029569
- Testing
- Rapamycin drug balloon angioplasty, Paclitaxel drug balloon angioplasty
- Volunteers
- 256 people
- Sponsor
- Shanghai Bomaian Medical Technology Co., Ltd
Peripheral Vascular Disease
Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia…
- Trial name
- NCT00067041
- Testing
- Remodulin (treprostinil sodium) Injection
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- United Therapeutics
Arterial Thromboembolism, Venous Thromboembolism
Aspiration Thrombectomy Using the Symphony or Prodigy System
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- CLEAR-IT (NCT07350499)
- Testing
- Prodigy Thrombectomy System, Symphony Thrombectomy System
- Where
- 13 sites in United States
- Volunteers
- 750 people
- Sponsor
- Imperative Care, Inc.
Peripheral Arterial Disease, Critical Lower Limb Ischemia
Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon
To evaluate the safety and performance of the Sundance™ DCB in subjects with occlusive disease of the infrapopliteal arteries.
- Trial name
- SWING (NCT04107298)
- Testing
- SUNDANCE™ Drug Coated Balloon
- Where
- 8 sites in Australia, Austria and 3 more
- Volunteers
- 35 people
- Sponsor
- SurModics, Inc.
Femoral Artery Stenosis, Popliteal Artery Stenosis
MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery
The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the proximal popliteal artery…
- Conditions
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
- Trial name
- MDT-2113 SFA (NCT01947478)
- Testing
- MDT-2113 Drug-Eluting Balloon, Standard angioplasty balloon
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Medtronic Endovascular
Peripheral Arterial Disease Below the Knee, Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization
Below-the-Knee Interventions for Limb Salvage: Use of Multifunctional Angioplasty Balloon Catheters
Below-the-Knee Interventions for Limb Salvage: Use of Multifunctional Angioplasty Balloon Catheters ("BTK Multicath Registry") A non-randomized clinical registry This study is designed to obtain preliminary data on clinically…
- Trial name
- NCT06906055
- Testing
- Multicath, Standard of Care (SOC)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Summa Therapeutics, LLC
Peripheral Artery Disease
Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries
Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as LifeStent) for treatment of long (10-24 cm) lesions…
- Trial name
- NCT02278991
- Testing
- Lutonix Drug Coated Balloon
- Where
- 12 sites in Germany, Greece and 1 more
- Volunteers
- 149 people
- Sponsor
- C. R. Bard